RGNX
REGENXBIO Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-02 | PAKOLA STEVE |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
Common Stock
|
2,161 |
| 2026-07-02 | PAKOLA STEVE |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
Common Stock
|
2,161 |
| 2026-07-02 | PAKOLA STEVE |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Options (Right to Buy) (Direct)
The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer. |
Stock Options (Right to Buy)
|
2,161 |
| 2026-07-01 | PAKOLA STEVE |
Chief Medical Officer |
Convert↓
Filing footnotes — Stock Options (Right to Buy) (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan. The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer |
Stock Options (Right to Buy)
|
36,725 |
| 2026-07-01 | PAKOLA STEVE |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
Common Stock
|
36,725 |
| 2026-07-01 | Simpson Curran |
Director, Chief Executive Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on July 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on July 1, 2026. |
Common Stock
|
6,818 |
| 2026-07-01 | PAKOLA STEVE |
Chief Medical Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
Common Stock
|
36,725 |
| 2026-06-30 | Simpson Curran |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2026. |
Common Stock
|
1,453 |
| 2026-06-29 | PAKOLA STEVE |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $11.00 to $11.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
19,608 |
| 2026-05-29 | MIGAUSKY GEORGE V |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
Common Stock
|
9,807 |
| 2026-05-29 | KARABELAS ARGERIS N |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
Common Stock
|
9,807 |
| 2026-05-29 | MIGAUSKY GEORGE V |
Director |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Stock Options (Right to Buy)
|
46,600 |
| 2026-05-29 | Tasse Daniel |
Director |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Stock Options (Right to Buy)
|
46,600 |
| 2026-05-29 | Bennett Jean |
Director |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Stock Options (Right to Buy)
|
46,600 |
| 2026-05-29 | STUMP DAVID C |
Director |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Stock Options (Right to Buy)
|
46,600 |
| 2026-05-29 | Bennett Jean |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
Common Stock
|
9,807 |
| 2026-05-29 | Tasse Daniel |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
Common Stock
|
9,807 |
| 2026-05-29 | KARABELAS ARGERIS N |
Director |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
The option will vest in 12 equal monthly installments following May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Stock Options (Right to Buy)
|
46,600 |
| 2026-05-29 | Mills Kenneth T. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
Common Stock
|
9,807 |
| 2026-05-29 | Mills Kenneth T. |
Director |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Stock Options (Right to Buy)
|
46,600 |
| 2026-05-29 | Fox Allan M. |
Director |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Stock Options (Right to Buy)
|
46,600 |
| 2026-05-29 | Glucksmann Alexandra |
Director |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Stock Options (Right to Buy)
|
46,600 |
| 2026-05-29 | Glucksmann Alexandra |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
Common Stock
|
9,807 |
| 2026-05-29 | Zachary Jennifer |
EVP, General Counsel |
Award↑
Filing footnotes — Stock Options (Right to Buy) (Direct)
The option will vest on May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Stock Options (Right to Buy)
|
46,600 |
| 2026-05-29 | Zachary Jennifer |
EVP, General Counsel |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
Common Stock
|
9,807 |
| 2026-05-29 | STUMP DAVID C |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
Common Stock
|
9,807 |
| 2026-05-29 | Fox Allan M. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
Common Stock
|
9,807 |
| 2026-05-11 | PAKOLA STEVE |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $11.00 to $11.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
15,309 |
| 2026-03-10 | PAKOLA STEVE |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan. |
Common Stock
|
5,124 |
| 2026-02-01 | PAKOLA STEVE |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2026. |
Common Stock
|
5,267 |
| 2026-02-01 | Christmas Patrick J. |
Chief Strategy & Legal Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2026. |
Common Stock
|
4,700 |
| 2026-01-27 | Mills Kenneth T. |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
The previously granted option, representing a right to purchase a total of 225,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. |
Common Stock
|
225,000 |
| 2026-01-27 | Mills Kenneth T. |
Director |
Convert↓
Filing footnotes — Stock Options (Right to Buy) (Direct)
The previously granted option, representing a right to purchase a total of 225,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. |
Stock Options (Right to Buy)
|
225,000 |
| 2026-01-27 | Mills Kenneth T. |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to satisfy the exercise price and pay taxes upon the exercise of options originally granted to the reporting person on January 28, 2016, which were set to expire on January 28, 2026. The number of shares withheld was determined based on the closing price of the issuer's common stock on January 27, 2026. The transaction did not involve any open-market sale of securities. |
Common Stock
|
221,753 |
| 2026-01-06 | Christmas Patrick J. |
Chief Strategy & Legal Officer |
Award↑
Filing footnotes — Stock Options (Right to buy) (Direct)
25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. |
Stock Options (Right to buy)
|
39,650 |
| 2026-01-06 | Chan Mitchell |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Options (Right to buy) (Direct)
25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. |
Stock Options (Right to buy)
|
39,650 |
| 2026-01-06 | Simpson Curran |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. |
Common Stock
|
144,864 |
| 2026-01-06 | Malzahn Craig |
Chief Technology Officer |
Award↑
Filing footnotes — Stock Options (Right to buy) (Direct)
25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. |
Stock Options (Right to buy)
|
35,402 |
| 2026-01-06 | Christmas Patrick J. |
Chief Strategy & Legal Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. |
Common Stock
|
73,749 |
| 2026-01-06 | Simpson Curran |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Options (Right to buy) (Direct)
25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. |
Stock Options (Right to buy)
|
233,651 |
| 2026-01-06 | PAKOLA STEVE |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Options (Right to buy) (Direct)
25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer. |
Stock Options (Right to buy)
|
35,402 |
| 2026-01-06 | Malzahn Craig |
Chief Technology Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. |
Common Stock
|
65,847 |
| 2026-01-06 | Chan Mitchell |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. |
Common Stock
|
73,749 |
| 2026-01-06 | PAKOLA STEVE |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer. |
Common Stock
|
65,847 |
| 2026-01-02 | PAKOLA STEVE |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 3, 2022, January 3, 2023, January 2, 2024 and January 2, 2025. The number of shares withheld was determined on January 2, 2026 based on the closing price of the issuer's common stock on December 31, 2025. |
Common Stock
|
18,247 |
| 2026-01-02 | Christmas Patrick J. |
Chief Strategy & Legal Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 3, 2022, January 3, 2023 and January 2, 2024. The number of shares withheld was determined on January 2, 2026 based on the closing price of the issuer's common stock on December 31, 2025. |
Common Stock
|
9,793 |
| 2026-01-02 | Malzahn Craig |
Chief Technology Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 3, 2022, January 3, 2023, and January 2, 2024. The number of shares withheld was determined on January 2, 2026 based on the closing price of the issuer's common stock on December 31, 2025. |
Common Stock
|
1,238 |
| 2026-01-02 | Simpson Curran |
Director, Chief Executive Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 3, 2022, January 3, 2023, January 2, 2024 and January 2, 2025. The number of shares withheld was determined on January 2, 2026 based on the closing price of the issuer's common stock on December 31, 2025. |
Common Stock
|
18,559 |
| 2025-12-31 | Simpson Curran |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025. |
Common Stock
|
951 |
| 2025-10-09 | Simpson Curran |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
This transaction was effected pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $12.50 to $12.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
20,811 |